News | January 03, 2024
WuXi XDC partners with IntoCell to accelerate ADC discovery and development
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
AMI to become part of Enpro’s Sealing Technologies Segment
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
Sirius JV will be owned 51% by Sirius and 49% by Adani
Karkinos Healthcare has demonstrated exceptional dedication to privacy, setting a commendable example for businesses navigating the complexities of the digital landscape
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Ecolab’s continued leadership position on renowned sustainability indices demonstrates the company’s record of advancing sustainable growth
Subscribe To Our Newsletter & Stay Updated
